RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
AstraZeneca announced China approval for Tagrisso (osimertinib) as a first-line treatment for non-small cell lung cancer (NSCLC) in patients with EGFR exon 19 deletions or exon 21 (L858R) substitutions. In a Phase III trial, Tagrisso increased progression-free survival to 18.9 months, an improvement over 10.2 months for standard EGFR drugs. About 30%-40% of China NSCLC patients have EGFR mutations, an unusually high number. Previously, Tagrisso was approved in China as a second-line treatment for a similar group of patients.
